Cencora, Inc. $COR Shares Sold by Seeds Investor LLC

Seeds Investor LLC lessened its position in shares of Cencora, Inc. (NYSE:COR) by 25.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 983 shares of the company’s stock after selling 333 shares during the quarter. Seeds Investor LLC’s holdings in Cencora were worth $295,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC raised its position in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Costello Asset Management INC purchased a new position in shares of Cencora during the 1st quarter worth $28,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Cencora during the 1st quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the 2nd quarter valued at about $61,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in Cencora in the second quarter valued at about $61,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 46,640 shares of company stock valued at $14,099,338 in the last quarter. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $365.56 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $369.38. The firm has a market cap of $70.87 billion, a PE ratio of 37.61, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The company’s 50 day moving average is $327.70 and its two-hundred day moving average is $304.57.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on COR. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Mizuho raised their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird lifted their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.